Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Summary

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications